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Introduction
In 1967, Numerof [1] stated that nuclear medicine has grown 
in recent years from an esoteric field populated by a small group 
of closely allied health care providers into large multidisciplinary 
medical teams with a scope of practice that cuts across multiple 
disciplines. This observation rings true even more so today. There are 
two requirements necessary in any nuclear medicine procedure. First 
the a drug (radiopharmaceutical) must be available, and secondly it 
has to be properly labelled as a tracer. The field of radiopharmacy and 
radiopharmaceutical has grown substantially since 1924, when Herman 
Blumgart conducted the first clinical tracer studies by injecting radon 
and later, solutions of 214-Bi, into one arm of a patient and observing 
the time it took to reach the other arm [2].
According to Mather [3] radiopharmacy is scientifically recognised 
as an essential sub-speciality of nuclear medicine. Without radiophar-
maceuticals, the “food” of nuclear medicine, no radiodiagnostic or ra-
diotherapeutic procedures could be performed, and without progress 
in radiopharmacy medical speciality, like nuclear medicine, will, ulti-
mately, wither and die. Radiopharmaceuticals serve two complemen-
tary roles as a diagnostic tool. The first is as a measure bioavailability: 
the labeled compound is administered to the patient and some aberrant 
physiological or biochemical process leads to an abnormal distribution 
of the compound in the patient. The second role the radiopharmaceu-
tical is as a tracer for particular physiological or biochemical process 
and the time course of its distribution is used to quantity the biological 
process [4,5].
The last few decades have seen an immense growth in availability 
and consumption of medicines. Whilst most consumers derive 
far more benefit than harm, a proportion of patients experience 
undesirable side effects or adverse drug reactions (ADR) (from the use 
of medicines at even the recommended dosage and dosing schedule [6]. 
Radiopharmaceuticals are no different; however, the consequence of an 
ADR can be much more severe. Moreover, the interference is directly 
related to the quality of the exam which may result in a false positive 
reaction. 
Jones [7] has already alerted to the fact that although ADRs can 
appear as isolated, specific clinical events that may be related to a 
number of factors in the patient’s background and environment, in 
many situations it may not appear early as a detectable clinical event, 
but rather remain clinically silent. Again as drugs, radiopharmaceuticals 
are no different. Other descriptive characteristics of ADRs concern 
their acuteness or latency relative to drug exposure, their severity, and 
their frequency or incidence. The latter information, although highly 
desirable, is usually not well-defined for most cases of ADR, with the 
exception of the common ones defined in clinical trials. The incidence 
of rarer effects is known for just a few drugs, as only recently have 
epidemiological methods and studies been directed towards the study 
of pharmacovigilance and post-market drug safety.
According to Silberstein and Ryan [8], significant adverse drug 
reaction should be reported must include the following: 
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Abstract
Too many false-positive and adverse reactions related to radiopharmaceuticals take place every day in hospitals 
routine, but many are not reported or even sensed. Information concerning these kind of reactions is not abundant 
and nuclear medicine staff is usually overwhelmed by this information. As every healthcare intervention carries some 
risk of harm, clinical decision making needs to be supported by a systematic assessment of the balance of benefit to 
harm. A systematic review that considers only the favorable outcomes of an intervention, without also assessing the 
adverse effects and false positives reactions, can mislead by introducing a bias favoring the intervention that in the 
case o radiopharmaceuticals may to render a important factor related not even to the quality of the drug but even to 
the quality of the diagnosis. The results suggest a logical framework to make decisions in reviews that incorporate 
false positive and adverse reactions. Also, was explored situations where a comprehensive investigation of false 
positive reactions and adverse effects was warranted and suggest strategies to identify practicable and clinically 
useful outcomes. We concluded that there is the necessity to include and to recognize how strategic choices made in 
the review process determine what harms are found, and how the findings may affect clinical decisions. Researchers 
undertaking a systematic review that incorporates false positive reaction and adverse reactions must understand the 
rationale for the suggested methods and be able to implement them in their review. Beyond a world effort should be 
made to report as many cases of false positive and adverse reactions with radiopharmaceuticals as possible. Only if 
this is done a complete picture of false positive reactions with radiopharmaceuticals can be drawn.
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1. Untoward effects whether observed frequently or rarely
2. Untoward effects never before seen following administration of 
the radiopharmaceutical
3. Only life-threatening or fatal reactions from drugs other than 
radiopharmaceuticals
4. Reactions unanticipated from unknown pharmacological action 
of a nonradioactive pharmaceutical 5. Anaphylactoid or allergic 
reactions.
Nonetheless, despite the potential for severe ADR in patients who 
are using a radiopharmaceutical, the actual incidence of ADR is rarer 
when compared to other drugs for therapeutic purposes. Nevertheless 
the incidence of false positives remain significant [9]. The results of both 
ADR and false positives are linked to radiopharmaceuticals show just 
a few incidents, but that may be due to the small number of reported 
cases. Studies demonstrated that only 10% of possible reactions are 
actually reported [10]. Besides, the great majority of these are neither 
serious/life-threatening nor require active treatment [10].
Estimates of adverse reaction prevalence and false positive reactions 
are difficult to assess, partly because of physician/doctor ignorance of 
available reporting schemes. The reasons for not filling out adverse 
reactions reporting forms are numerous, and may include subjective 
nature of interpreting an adverse reactions, emotional considerations 
such as a physician’s anxiety about potential liability, or the belief that 
the reaction is common knowledge [8,11].
Methodology
As with any systematic review of effectiveness, a clearly focused 
research question is essential in a review of adverse effects (ADR) 
and false positive reactions. Relevant questions will be those that 
are directly aimed at guiding the decisions of clinicians, consumers, 
researchers and policymakers, in this direction, a protocol should be 
developed for the systematic review and details of the research question 
specified, including the types of participants, interventions/exposures, 
comparisons, outcomes, and study designs to be included. Selection 
of outcomes and study type requires careful consideration in reviews 
of false positive reactions and adverse affects and should be made by 
specialized staff. Systematic reviews which include false positive and 
adverse reactions are likely to make more than one comparison. In 
such a case, the early stages of the protocol should specify what the 
main comparisons will be and whether the review will consider both 
beneficial and not beneficial reactions, in this case false positive 
reactions and adverse effects. The resources devoted to studying false 
positive reactions and adverse effects outcomes should reflect the 
importance of the treatment in context. For example, if a treatment 
confers little benefit and is seldom used, its adverse effects or even 
its false positive reactions may not be worth a detailed evaluation. 
Some interventions will require an exhaustive analysis of all harmful 
outcomes, while others may require a less thorough investigation [12].
Usually, when the focus of the research question is purely on 
safety and or tolerability, the effectiveness of the treatment is already 
known or defined [13]. However, in some instances reviewers intend 
to evaluate adverse effects and/or false positive reactions as part of a 
combined review that also covers beneficial outcomes. Reviews that 
aim to evaluate benefit and harm together will usually require a more 
complex study design that can efficiently handle different sets of studies 
for various outcomes. Using different search strategies and/or eligibility 
criteria for studies of benefit and harm will generate two or more diverse 
groups of eligible studies. Unlike reviews of effectiveness, where all 
beneficial outcomes are likely to be well recognized beforehand, in these 
types of studies specific adverse effects associated with a therapeutic 
intervention may or may not be known in advance of the review. It 
may not be possible to specify in advance which effects will be most 
relevant to the review. Moreover, the research question about safety and 
tolerability in a review can be broad or narrow in scope. In general, 
reviewers who have already identified important safety concerns should 
carry out a narrow-focused evaluation covering particular aspects of 
the relevant adverse effects and false positive reactions. In relation to 
the types of studies no single recommendation is possible here, and any 
decisions have to be made case by case. The decision on what types 
of studies to include will depend primarily on the main focus of the 
research question, balancing the elements of type of adverse effects(s) 
of interest, rigour in searching, and time and resources available. The 
systematic evaluation of new or rare adverse effects and even specifically 
false positive reactions may require the inclusion of other study designs: 
cohort, case-control, cross-sectional, and even case series. Specific to 
adverse reactions a recommendation is important: authors planning 
to use such additional data sources should realize that estimates of 
the frequencies of adverse effects from published case reports and 
spontaneous reporting may differ greatly from the results obtained 
from a meta-analysis of double-blind, randomized controlled trials 
[14]. A study comparing adverse outcomes from randomized and non-
randomized studies found that the latter often yield lower estimates of 
absolute risk of harm [15]. 
The location and the selection of studies by the authors is one of the 
most important step in a systematic review. The authors need to develop 
a literature search strategy based on key elements in their research 
question: population, intervention (plus acceptable comparators), and 
outcomes. The review question determines the nature of the search 
strategy. In this study a review of the literature on adverse reaction 
and false positive reactions with radiopharmaceuticals was carried out. 
Computerized databases for radiopharmaceuticals were searched, such 
as MEDLINE, EMBASE, International Pharmaceutical Abstracts and 
Science Citation Index, published between 1956 and 2007 (April). The 
searches were supplemented with manual searches of bibliographies of 
the published articles on major radiopharmacy textbooks, and in the 
Cochrane Database of Systematic
Two main approaches can be used, each with its own limitations; 
in the case of a systematic review of adverse effects and false positive 
reactions related to the FDG-18. They are best combined to maximize 
sensitivity: 
Electronic databases using index terms 
Electronic databases using index terms (also called controlled 
vocabulary or thesaurus terms): a) Index terms such as MeSH (Medical 
Subject Headings) in MEDLINE and EMTREE in EMBASE are assigned 
to records in electronic databases to describe the studies. Subheadings 
can also be added to index terms to describe specific aspects – for 
example, side effects of drugs, or complications of surgery. In this study 
the indexing terms used were: adverse reactions; contraindications, 
complications, false positive reactions, misdiagnosis, false negative; 
toxicity and others. b) Indexing terms in MEDLINE and EMBASE: 
Within a database, studies may be indexed in three different ways: 
(i) under the name of the intervention together with a subheading 
to denote that adverse effects and false positive reactions occurred, 
for example, FDG/adverse effects, PET/complications; (ii) under 
the adverse event itself, together with the nature of the intervention, 
for example, Misdiagnosis/and FDG/, arthroplasty/and surgery/; or 
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(iii) occasionally only under the adverse event, for example, adverse 
reaction/chemically-induced. Thus, no single index or subheading 
search term can be relied on to identify all data on adverse effects, but a 
combination of index terms and subheadings will help to detect reports 
of major adverse effects which the indexers have considered significant 
[16,17].
Electronic databases using free-text terms (‘text words’) 
Electronic databases using free-text terms (‘text words’) Terms used 
by authors in the title and abstract of their studies can be searched on 
databases of electronic records using free-text terms. Two problems 
seriously limit the value of free-text searching: 
•	 Authors commonly use a wide range of terms to describe 
adverse effects, both in a general sense (toxicity, side-effect, 
adverse-effect) and more specifically (eg, lethargy, tiredness, 
malaise may all be used synonymously). An author of a review 
may not know all these terms in advance but should try to 
include as many relevant synonyms as possible.
•	 The free-text search does not detect adverse effects or false 
positive reactions not mentioned in the title or abstract of the 
study in the electronic record (even though they appear in the 
full report) [12,17].
A sensitive free-text search should incorporate this potentially 
wide variety of synonymous terms used to denote data on adverse 
effects in studies, while also taking into account different conventions 
in spelling and variations in the endings of terms. So it is necessary to 
include singular and plural terms. These terms used to describe adverse 
effects and false positive reactions should then be combined with free-
text terms used to describe the intervention of interest. A systematic 
review with a focus adverse effects and false positive reactions, difficult 
to conduct for normal “cold” drugs the difficulty is only increase in the 
case of radiopharmaceuticals. Clearly no single approach will reliably 
yield all the studies that have data on adverse effects of an intervention. 
The search, therefore, needs to combine index terms and free-text terms 
and is likely to take several iterations. In deciding which combination 
of terms to use, authors will need to balance comprehensiveness 
(sensitivity) against precision. For example, an electronic search 
that retrieves 20,000 studies is likely to contain most of the relevant 
studies, but if only 300 (1.5%) are relevant it is very imprecise and 
resource intensive [12,18]. Review authors planning an exhaustive 
search may wish to consider checking other sources of information on 
adverse effects and false positive reactions, which include spontaneous 
reporting systems and data from regulatory agencies both done in this 
study as described above. An important factor that must be considered 
is that there is often a major trade-off between the comprehensiveness 
and the quality of the adverse effects data and false positive reactions 
data included in a systematic review. Including evidence that is likely 
to be biased, even if no better evidence exists, may lead to biased 
conclusions. All included data should be critically discussed and 
rigorously appraised. 
One cannot conclude from ‘zero events detected’ that an 
intervention does not cause a suspected adverse effect or even a false 
positive reaction. However, we can use the rule of three (for sample 
sizes > 30), to estimate the upper limit of the 95% confidence interval 
for the probability of the adverse effect [19]. If no events were detected 
in n trial participants, the upper limit of the 95% confidence interval 
for the probability of the adverse event is 3/n. In effect, this gives us a 
good idea of what the worst-case scenario could be, if no adverse events 
have occurred so far in our sample. For example, if no adverse effects 
occur in 300 participants, then any adverse effects associated with 
the intervention might be as frequent as 1 in 100, but are unlikely to 
be more frequent. Note that studies with no events in either arm can 
be included in a meta-analysis of risk differences, but they cannot be 
included in a meta-analysis of odds ratios or risk ratios.
It is important to remember that a systematic review is not 
synonymous with a meta-analysis. In many circumstances adverse 
effect and false positive information is best summarised in a qualitative 
or descriptive manner. For instance, data derived from divergent 
sources cannot be combined because of different study design, different 
populations or, different data collection methods. It may not be possible 
to compare benefits and harms directly. In practice this means that 
adverse effects from case reports, case series, cohorts, and case controls 
cannot all be pooled together using standard meta-analysis principles. 
Further, the data from non-randomized studies are more prone to 
bias, and are often heterogeneous; suspected heterogeneity need to be 
considered before such studies are combined to generate a summary 
statistics.
Sarcoid reaction to FDG
In recent years PET scans with fludeoxyglucose (FDG-18) have 
been playing an increasingly important role in the evaluation of the 
response to induction chemotherapy, as well as in the detection of 
primary tumor and metastatic lesions in several malignancies [20-22]. 
In one reported case a 66 year-old man was referred to the hospital for 
investigation of an abnormal shadow measuring 5.2cm in diameter in 
the left upper lung field on a chest X-ray. The patient was eventually 
diagnosed with lung cancer classified as clinical stage IIIA (T2N2M0) 
and underwent induction chemotherapy with paclitaxel. 
On the other hand, an FDG-PET scan prior to the chemotherapy 
demonstrated accumulation only in the tumor and not in the 
mediastinal node. This result led to suspicion that the disease had 
progressed to N3 lesions. Hence the patient underwent a biopsy of the 
right supraclavicular lymph node and the mediastinal lymph nodes by 
mediastinoscopy. All dissected lymph nodes showed sarcoid reactions 
and no tumour cells were found to be pathological. The patient had 
no clinical symptom of sarcoids and the chest X-ray did not show 
streaks and/or spots. The conclusion was that a sarcoid reaction of the 
mediastinal lymph nodes probably led to the abnormal accumulation 
of FDG without tumor metastasis. Therefore, in patients with FDG-
PET positive results, it is necessary to verify lymph node pathologically 
using mediastoscopy, because this type of adverse reaction (sarcoid 
reaction) may occur and change the clinical conduction [20]. 
Another case of sarcoid reaction occurred with a 57-year-old 
female patient with a history of diffuse large B-cell lymphoma, 
involving the lungs and spleen. This patient received 8 courses of CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone) and rituxan 
therapy. After 4 months she underwent a PET-CT scan that showed 
increased uptake in the spleen. This patient underwent a splenectomy 
due to the suspicion of recurrence. The results of the pathology showed 
noncaseating granulomas consistent with sarcoid-like reaction. 
These two cases show the importance of the sarcoid-reaction and the 
importance of a pathological analysis in case of suspicion [23].
False Positive Reactions
Another case of false positive uptake, described by Iwasaki et al. 
[24] with a 57-year-old woman, demonstrated that fused FDG-PET and 
PET/CT images performed to analyze pulmonary suture abscess can 
be confused with lung cancer, because the abscess, as an inflammatory 
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process, increase the uptake of FDG by the lesion. During the analysis, 
the scan data can be misunderstood as a lung cancer. A report made 
by Aide et al. [25] described a false-positive uptake of FDG in three 
patients related to foreign body reaction. According to the authors 
remote mesh prostheses can induce FDG uptake because of persistent 
foreign body reaction. Consequently, in each scan an unexpected pelvic 
focus was noticed on FDG PET, since that is where the prostheses were. 
The authors confirmed that the medical history of patients should be 
carefully reviewed to avoid false-positive results.
Hurwitz [26] described a 54-year-old woman with a treated 
carcinoma of the breast. There was spontaneous rupture of an implant 
placed previously as part of breast reconstruction. An FDG-PET scan 
was carried out and disclosed intense uptake in these nodes. Lymph 
nodes biopsy, however, demonstrated benign inflammatory reaction 
and no recurrence of malignancy. A false-positive PET scan may occur 
when FDG is taken up in a ruptured breast implant and data should be 
carefully analyzed in these cases. 
Other case of false-positive was described by Modi et al. [27] with 
a 73-year-old man that received Teflon to treat a vocal cord paresis and 
showed abnormal uptake of FDG during a PET scan. According to the 
authors the false-positive response was due a foreign body reaction (as 
described above) related to Teflon.
An important case of false-positive reaction is related to the hip 
arthroplasty. A retrospective and prospective study conducted by 
Zhuang et al. [28] with nine patients and 710 patients respectively, 
concluded that, following hip arthroplasty, non-specifically increased 
FDG uptake around the head or neck of the prosthesis persists for 
many years, even in patients without any observable complications. 
Therefore, to minimize the number of false-positive results with PET 
studies, caution should be exercised when interpreting FDG uptake 
around the head or neck portion of prostheses. 
Recently another case o false positive reaction was published. 
A 70-year-old woman receiving long-term corticosteroids therapy 
for sarcoidosis presented with hip pain. She underwent whole-
body technetium 99m methylene diphosphonate bone scintigraphy 
to exclude vascular necrosis of the femoral head. Although there 
was no suggestion of vascular necrosis, multiple areas of increased 
activity were present in the axial and proximal appendicular skeleton. 
These findings suggested multiple skeletal metastases. A computed 
tomography scan of her chest showed bilateral pulmonary opacities 
and an infiltrating process involving the mediastinum and both hila. A 
computed tomography scan of her abdomen identified splenomegaly 
and lymphadenopathy. The differential diagnosis included small-
cell lung cancer, sarcoma, lymphoma and infection. The patient had 
received a diagnosis of sarcoidosis 5 years earlier when she presented 
with lymphadenopathy and night sweats. The initial workup included 
a computed tomography scan that showed lymphadenopathy and an 
axillary lymph-node biopsy that revealed noncaseating granulomata. 
The radiologist reviewing the current computed tomography scan did 
not receive this background information and suspected a malignant 
process. The patient’s respirologist subsequently performed bone-
marrow biopsies, which demonstrated noncaseating granulomata 
consistent with skeletal sarcoidosis. The patient’s condition has been 
stable, and a repeat bone scan after 2 years of follow-up showed no 
change. This case demonstrates a rare but important manifestation 
of sarcoidosis mimicking skeletal metastases on bone scintigraphy. It 
underscores the importance of providing complete clinical information 
to the imaging service to facilitate accurate diagnostic interpretation 
[29].
Conclusion
The literature review on this topic reveals only a few studies were 
made that address the issue of safety (ADR) and effectiveness (false 
positives) with radiopharmaceuticals, despite their increase use; this 
disproportion between increase use and low reporting would suggest 
that there is a tremendous amount of possible underreporting of 
ADR and false positives with radiopharmaceuticals usage. As a sizable 
proportion of these cases are suspected have hidden false positives, this 
is a clear justification (if indeed any is needed) for further investigations 
in this area of research concerning ADR and false positives of 
radiopharmaceutical products.
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